Learn how to use IsoPSA to better determine which patients to defer for biopsy and which to monitor more closely. Accurate, simple, proven to detect csPCa Determining which patients need a prostate biopsy can be difficult due to PSA's low specificity. IsoPSA is a blood test designed to more accurately detect high-grade prostate cancer. With greater specificity for csPCa, this test is also easy to use, requiring no DREs or patient clinical information. Results are not affected by BPH drugs, prostatitis, or physical activity. Backed by an extensive portfolio of publications and clinical evidence, IsoPSA enhances risk assessment to support more informed and confident biopsy decisions. Predict future csPCa risk to improve patient monitoring A recent study in Urology by Nour Abdallah et al. demonstrates that IsoPSA is a powerful predictor of csPCa over time. The study's longitudinal data demonstrates that one IsoPSA result is predictive of future risk of csPCa. These findings indicate that IsoPSA can help clinicians defer biopsy in low-risk patients while identifying those at higher risk who may require closer follow-up. See how IsoPSA supports better biopsy decisions On May 22 at 1:00 PM ET, Arpeet Shah, MD, Director of APP Program, Associated Urological Specialists (AUS) will join us for a webinar on incorporating IsoPSA into your practice. Dr. Shah will share evidence-based strategies for managing biopsy-naïve and repeat-biopsy patients, including how he uses IsoPSA with mpMRI to guide decisions. He'll also present case studies that highlight best practices for improving biopsy decisions and predicting future csPCa risk.  REGISTER  © 2025 Cleveland Diagnostics, Inc. Privacy Policy | Unsubscribe IsoPSA is a laboratory developed test from Cleveland Diagnostics, Inc., which is regulated under CLIA and qualified to perform high-complexity clinical testing.